ITEMS IN AFP WITH KEYWORD:
Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disease that affects approximately one out of every 500 persons. The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have updated guidelines on the diagnosis and treatment of HCM.
Jul 1, 2012 Issue
Adding ACE Inhibitors or ARBs to Standard Therapy for Stable Ischemic Heart Disease [Implementing AHRQ Effective Health Care Reviews]
Are there clinical advantages to augmenting standard therapy for stable ischemic heart disease with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)?
Major changes addressed in the American Heart Association's (AHA) 2011 guidelines on cardiovascular disease (CVD) are that benefits and risks found in the clinical practice setting were strongly considered, and recommendations were not based solely on benefits found in the clinical research setting....
Jul 15, 2011 Issue
ACCF/AHA Release Guideline for Early Cardiovascular Risk Assessment [Practice Guidelines]
Atherosclerotic cardiovascular disease is the leading cause of death among adults in the United States. Because coronary heart disease (CHD) has a long asymptomatic latent period, there is an opportunity for early preventive measures. The American College of Cardiology Foundation (ACCF) and the Amer...
Jun 15, 2011 Issue
Aspirin for the Prevention of Cardiovascular Disease: Recommendation Statement [U.S. Preventive Services Task Force]
The U.S. Preventive Services Task Force (USPSTF) recommends the use of aspirin in men 45 to 79 years of age when the potential benefit of a reduction in myocardial infarctions (MIs) outweighs the potential harm of an increase in gastrointestinal (GI) hemorrhage.
Jun 15, 2011 Issue
Aspirin for the Prevention of Cardiovascular Disease [Putting Prevention into Practice]
Case study: K.T., a 48-year-old man, presents for a routine office visit. He is worried about cardiovascular disease (CVD) and asks whether he should take daily aspirin to lower his risk. His blood pressure is 120/60 mm Hg, and his total cholesterol is 180 mg per dL (4.66 mmol per L), with a low-den...
Dec 15, 2010 Issue
Thiazolidinedione Therapy for Managing Metabolic Syndrome [FPIN's Clinical Inquiries]
There is no patient-oriented evidence supporting the use of TZD therapy in patients in the general population who have metabolic syndrome. Rosiglitazone (Avandia) use decreases cardiovascular morbidity and mortality in patients with metabolic syndrome who are undergoing coronary stenting.
The American College of Chest Physicians (ACCP) wrote a consensus statement to influence clinical practice and provide suggestions regarding the management of dyspnea in patients with advanced lung or heart disease.
To prevent heart attack, stroke, or death, the American Heart Association recommends estimating patients’ absolute risk of having a coronary heart disease (CHD) event in 10 years. Before physicians adopt routine risk calculation, we should use the evidence to determine the best use of our patients’ time and resources.
Does counseling to increase physical activity lead to increased physical activity in healthy persons without existing CVD? What are the health benefits of increasing physical activity in relation to cardiovascular outcomes in healthy persons without existing CVD?